Non-convulsive status epilepticus resistant to benzodiazepines

J H LIVINGSTON AND J K BROWN
Royal Hospital for Sick Children, Edinburgh

SUMMARY We describe the failure of an intravenous benzodiazepine to control non-convulsive status epilepticus occurring in six patients with the Lennox-Gastaut syndrome. In one patient the benzodiazepine induced a paradoxical response with clinical and electroencephalographic seizures.

Non-convulsive status epilepticus is a rare but serious complication of seizure disorders in childhood, particularly in the age dependent epileptic encephalopathies, such as the Lennox-Gastaut syndrome.1 The effects of non-convulsive status on cerebral metabolism are uncertain. In children with intractable seizure disorders, however, the incidence and degree of subsequent mental retardation is greater in those who have had one or more episode of non-convulsive status compared with those who have had no episodes.1,2 In addition, during these episodes, the children are very slow to react to any stimuli, are unable to concentrate, have no ability to learn, become disorientated and confused, and often lose speech. Episodes of non-convulsive status may last from a few hours up to several months.3 For these reasons such episodes are regarded by many as a paediatric emergency requiring aggressive treatment.

While it is recognised that non-convulsive status may be drug resistant, in general intravenous benzodiazepines have been considered to be the drugs of choice for this complication.2-4 Gastaut has gone as far as to say that all cases of absence status respond within a few minutes to intravenous benzodiazepines.5 We report here our experience with seven patients presenting in non-convulsive status treated with benzodiazepines.

Patients and methods

The patients reported here formed part of a group of 40 patients with intractable seizure disorders in whom testing of benzodiazepine sensitivity has been carried out. Nine out of the forty (23%) had an electroclinical diagnosis of the Lennox-Gastaut syndrome, and seven of these nine presented with at least one episode of non-convulsive status. These seven patients had testing of benzodiazepine sensitivity performed during the acute episodes of status and form the subject of this paper.

Details of the seven patients are shown in the Table. All patients were attending the paediatric epilepsy service at the Royal Hospital for Sick Children, Edinburgh. There were four boys and three girls. The mean age of presentation was 7 years (range 3–13 years). The aetiology in all cases was unknown, but in one patient it was presumed to be prenatal in origin as he showed dysmorphic features with microcephaly. The usual seizure type in most patients comprised drop attacks, complex absences, myoclonic jerks, and tonic seizures. All patients had presented with increased frequency in their usual seizures, followed by onset of unresponsiveness, drooling, and prolonged absences, in some cases associated with loss of speech and ataxia.

In all the patients the electroencephalogram (EEG) showed continuous or almost continuous slow spike or polyspike and wave of varying degrees of symmetry and synchrony. The duration of status as determined by history ranged from two days to five weeks (mean 10 days).

All patients were given intravenous benzodiazepines during continuous EEG monitoring. Five patients were given diazepam in a dose of 0.2–0.3 mg/kg, one was given clonazepam in a dose of 0.02 mg/kg, and one was given both clonazepam and diazepam.

Results

Examples of the EEG response to intravenous benzodiazepines are shown in the Figure. Only one
<table>
<thead>
<tr>
<th>Case No</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>M</td>
<td>M</td>
<td>F</td>
<td>F</td>
<td>M</td>
<td>M</td>
<td>M</td>
</tr>
<tr>
<td>Age (years)</td>
<td>13</td>
<td>5</td>
<td>7</td>
<td>8</td>
<td>7</td>
<td>5</td>
<td>2½</td>
</tr>
<tr>
<td>Past history</td>
<td>Febrile convulsions</td>
<td>Developmental delay, microcephaly, hyperactive</td>
<td>Prolonged and recurrent febrile convulsions</td>
<td>Recurrent febrile convulsions, afebrile convulsions, hyperactive</td>
<td>Tonic/tonic clonic seizure aged 5</td>
<td>Dyssomtic, microcephaly, developmental delay, onset absoences aged 2½</td>
<td>Onset infantile spasms at 6 months, mental retardation</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>Lennox-Gastaut Unknown</td>
<td>Lennox-Gastaut Unknown</td>
<td>Lennox-Gastaut Unknown</td>
<td>Lennox-Gastaut Unknown</td>
<td>Lennox-Gastaut Presumed prenatal</td>
<td>Lennox-Gastaut Unknown</td>
<td>Lennox-Gastaut Known</td>
</tr>
<tr>
<td>Aetiology</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Adverse seizures, drop attacks, absences, myoclonic tonic clonic</td>
<td>Drop attacks, absences, myoclonic tonic clonic</td>
<td></td>
</tr>
<tr>
<td>Usual seizure type</td>
<td>Drop attacks, tonic/ clonic, myoclonus</td>
<td>Drop attacks, absences, tonic/tonic clonic</td>
<td>Drop attacks, tonic/tonic clonic, absences, myoclonic tonic clonic</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drugs at time of presentation</td>
<td>None</td>
<td>None</td>
<td>Carbamazepine, clonazepam</td>
<td>Carbamazepine, valproate</td>
<td>Carbamazepine, primidone, acetazolamide, ethosuximide</td>
<td>Valproate</td>
<td>Valproate, carbamazepine</td>
</tr>
<tr>
<td>Previous use of benzodiazepines</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Clinical features</td>
<td>Drowsy, frequent brief twitches of mouth and hands, drooling</td>
<td>Ataxic, frequent brief twitches of hands, 'dazed appearance'</td>
<td>Drooling, unresponsive, unable 'to walk', brief myoclonic jerks, increase in tonic seizures</td>
<td>Frequent prolonged absences, drooling tonic/tonic clonic seizures, myoclonic jerks jerks</td>
<td>Increased frequency seizures, drooling, ataxic, unresponsive</td>
<td>Prolonged unresponsiveness, frequent atonic seizures, erratic myoclonus</td>
<td>Drowsy, ataxic, unresponsive, frequent drop attacks, increase in myoclonus</td>
</tr>
<tr>
<td>Estimated duration of status</td>
<td>Two days</td>
<td>Uncertain, probably several weeks</td>
<td>Continuous, moderate amplitude, irregular slow spike and slow waves</td>
<td>Continuous, moderate amplitude, irregular slow spike and slow waves</td>
<td>Very frequent generalised spike and wave at 2-5-3-5 Hz</td>
<td>Continuous, high amplitude, asynchronous slow spike and wave at 2 Hz, with occasional suppression</td>
<td>Continuous, high amplitude, slow spike and wave</td>
</tr>
<tr>
<td>Electroencephalogram appearance</td>
<td>Continuous, high amplitude, generalised slow spike and wave</td>
<td>Continuous, slow spike and wave at 2 Hz, right more than left</td>
<td>Continuous, slow spike and wave with runs of spike and slow waves</td>
<td>Almost continuous, generalised slow spike and wave with occasional high amplitude polyspikes</td>
<td>Increase in episode of suppression but still almost continuous paroxysmal activity</td>
<td>Complete suppression of paroxysmal activity, emergence of more normal background</td>
<td></td>
</tr>
<tr>
<td>Response to benzodiazepines</td>
<td>Paroxysmal response, induced tonic seizures</td>
<td>Modification of spike component but no change in background</td>
<td>No change</td>
<td>No change</td>
<td>No change</td>
<td>No change</td>
<td>No change</td>
</tr>
</tbody>
</table>

*Arch Dis Child: first published as 101.1364/adc.14 on 1 January 1987. Downloaded from http://adc.bmj.com/ on October 15, 2023 by guest. Protected by copyright.*
Non-convulsive status epilepticus resistant to benzodiazepines

A patient showed a positive response with complete abolition of paroxysms and improvement in clinical state after treatment with benzodiazepines. One patient (case 6) showed a change in his EEG with an increase in the number of episodes of suppression but still with virtually continuous paroxysmal spike and wave activity and no associated clinical improvement. One patient showed some modification of the spike component but continued with high amplitude slow wave background activity and no clinical change. One patient (case 1) had a paradoxical response with the onset 10 minutes after administration of benzodiazepines of paroxysms of rhythmic spikes at 10 per second followed by spike and wave. On each occasion these paroxysms were associated with a tonic seizure. Three patients showed no change in their EEG or clinical state.

Discussion

These results suggest that the benzodiazepines may not be the most effective treatment for non-convulsive status. It is well known, however, that the effects of the benzodiazepines are unpredictable and that patients’ sensitivity to the drugs may change with time, depending on such variables as current anticonvulsive treatment and seizure control.

Lagenstein reported a 57% response rate to intravenous benzodiazepines in 56 patients with a diagnosis of petit mal status. They also reported, however, a high relapse rate. In contrast, Tassinari found that only 15% of children with non-convulsive status associated with the Lennox-Gastaut syndrome showed EEG or clinical response to intravenous benzodiazepines.

Benzodiazepines act by enhancing γ-aminobutyric acid (GABA) mediated inhibition in the central nervous system by their action on the GABA-benzodiazepine/chloride ionophore complex. There are at least two pharmacologically distinct benzo-

Figure  (a) Example of non-response to administration of diazepam in case 3; (b) Paradoxical response occurring in case 1 associated with tonic seizure.
enable benzodiazepine receptors, and type 2 probably consists of several subunits. A recent hypothesis suggests that each benzodiazepine receptor has four different binding sites for the benzodiazepines and each of these sites can exist in three different conformations. It is thus theoretically possible for the benzodiazepines to increase, decrease, or have no effect on gabaergic transmission.

In addition, other anticonvulsants are known to interact directly at the benzodiazepine receptor or to have other effects on GABA mediated inhibition. As well as the conformational and interational changes that may occur in benzodiazepine receptors, it is also known that changes in receptor numbers may occur with chronic treatment, and thus both down regulation and up regulation of receptors have been described.

Five of the seven patients in this group had previously been on oral treatment with benzodiazepines and thus these mechanisms may explain their subsequent lack of response. Two of the patients, however, had no previous exposure to them and clearly down regulation of receptors could not explain the lack of response in these patients. It does seem, however, that the chronicity of the seizure disorder, together with the need for many different anticonvulsants taken over long periods, seem to make negative or paradoxical responses more likely.

The benzodiazepines are the most effective treatment for convulsive status epilepticus available and from this small series we would not suggest that they should be avoided in the treatment of non-convulsive status. These results illustrate, however, that many patients with non-convulsive status will not respond to them in the acute stage. We would emphasise the importance of continuous EEG monitoring during the treatment of these patients to assess the effects and watch for unusual or paradoxical responses that are more common in this group of patients. If diazepam has failed we would suggest a trial of clonazepam, although in our experience we have not seen anyone in non-convulsive status who has responded to clonazepam that did not respond to diazepam. These states are often very drug resistant, and many different therapeutic manoeuvres have been tried. It has been suggested that infusion of clormethiazole may enable benzodiazepine sensitivity to return, but this has not been our experience.

In patients who have become resistant to benzodiazepines after a previous response a drug holiday of several weeks may allow sensitivity to return. This approach would only have been applicable, however, to one of our patients in this study, as six of the seven were not on benzodiazepines at the time of testing. Clobazam has been suggested to be superior to the other benzodiazepines for chronic oral treatment. Our clinical impression is that, while it does seem more effective in other types of intractable seizure disorders, it has not proved to be an advance in patients with the Lennox-Gastaut syndrome.

If benzodiazepines have failed to control non-convulsive status we would suggest immediate treatment with either regular paraldehyde, infusion of clomethiazole, or possibly infusion of barbiturates or steroids.

Although there is increasing concern about the possible brain damage caused by recurrent bouts of non-convulsive status, treatment of these states remain frustratingly difficult with the current anticonvulsants at our disposal.

References

Correspondence to Dr J H Livingston, Department of Paediatric Neurology, Royal Hospital for Sick Children, Sciennes Road, Edinburgh EH9 1LF.

Received 15 July 1986